中文
Products

Flu A&B Antigen Test Kit

Flu A&B Antigen Test Kit (Quantum Dots)

Intended Use

For the in vitro quantitative detection of influenza virus A and influenza virus B antigens in human nasopharyngeal or oropharyngeal swab samples.

Flu A&B Antigen Test Kit

Clinical Department

Fever Clinic, Outpatient Department, Emergency Department, Respiratory Medicine Department, Paediatrics Department, Infectious Diseases Department, Clinical Laboratory, etc.

Product Parameters Clinical application

[Product Name]Flu A&B Antigen Test Kit

[Sample Type]human nasopharyngeal or oropharyngeal swab

[Intended Use]
For the in vitro quantitative detection of influenza virus A and influenza virus B antigens in human nasopharyngeal or oropharyngeal swab samples.

[Clinical Department]
Fever Clinic, Outpatient Department, Emergency Department, Respiratory Medicine Department, Paediatrics Department, Infectious Diseases Department, Clinical Laboratory, et.


Product Parameters

Item

Flu A&B (Quantum Dots)

Test Time

15-20min

Sample Type

human nasopharyngeal or oropharyngeal swab

Sensitivity

/

Storage Condition

4-30℃

Packing Specification

1 Test/Kit; 2 Tests/Kit; 5 Tests/Kit; 10 Tests/Kit; 20 Tests/Kit; 40 Tests/Kit


Flu A and Flu B are the primary pathogens causing seasonal influenza, with highly similar clinical manifestations such as fever, cough, sore throat, fatigue and myalgia. Accurate differentiation cannot be achieved based solely on clinical symptoms.

1. Combined testing enables simultaneous identification of Influenza A and B infections, eliminating diagnostic blind spots associated with single pathogen testing. Particularly during influenza peak seasons, it helps improve the accuracy of early diagnosis and guides targeted clinical management.

2. Confirming the specific influenza virus type facilitates the rational selection of antiviral treatment regimens in clinical practice, reduces unnecessary medication use and improves overall treatment efficiency.

3. Combined testing supports the dynamic monitoring of Influenza A and B prevalence trends, providing data underpinnings for epidemic early warning, optimisation of prevention and control measures and allocation of medical resources.


微信公众平台

官网二维码